Growth and sexual maturation during long-term treatment with risperidone.
OBJECTIVE
This study assessed the impact of risperidone on growth and sexual maturation.


METHODS
The pooled database of five studies included 700 children ages 5-15 years with disruptive behavior disorders. All evaluable patients had received risperidone for 11 or 12 months. Those evaluable for growth also had baseline and 11- or 12-month height measurements (N=350); girls >/=9 years and boys >/=10 years who were evaluable for sexual maturation also had baseline and 11- or 12-month Tanner staging (N=222).


RESULTS
Risperidone-treated children had a mean increase in height 1.2 cm greater than the reference population, and they experienced no delay in progression through Tanner staging. Transient increases in prolactin did not correlate with growth or sexual maturation.


CONCLUSIONS
In this retrospective analysis, there was no evidence of statistically or clinically significant growth failure or delay in pubertal onset or progression in children treated for up to 1 year with risperidone.
Dunbar
Fiona
F
Janssen-Ortho Inc., Toronto, Ontario, M3C 1L9 Canada.
Kusumakar
Vivek
V
Daneman
Denis
D
Schulz
Miklos
M
D000293:Adolescent; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006128:Growth / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008137:Longitudinal Studies; D011388:Prolactin / Q000097:blood / Q000187:drug effects; D012189:Retrospective Studies; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use*; D012741:Sexual Maturation / Q000187:drug effects* / Q000502:physiology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D011388:Prolactin; D018967:Risperidone